
Sign up to save your podcasts
Or


Hydroxychloroquine has evolved from a sleepy anti-malaria drug into a partisan litmus test over the future of COVID-19 treatment. Dan and Axios healthcare reporter Bob Herman dig into what we know about the drug, what we still don't, and why both matter.
PLUS: New money for small businesses and a way to help New York medical workers
By Axios4.3
689689 ratings
Hydroxychloroquine has evolved from a sleepy anti-malaria drug into a partisan litmus test over the future of COVID-19 treatment. Dan and Axios healthcare reporter Bob Herman dig into what we know about the drug, what we still don't, and why both matter.
PLUS: New money for small businesses and a way to help New York medical workers

7,588 Listeners

37,428 Listeners

1,358 Listeners

1,049 Listeners

9,526 Listeners

1,515 Listeners

2,008 Listeners

87,290 Listeners

32,324 Listeners

2,135 Listeners

252 Listeners

12,497 Listeners

2,022 Listeners

4,366 Listeners

15,892 Listeners

10,746 Listeners

3,521 Listeners